Risk of Secondary Immune Thrombocytopenia following Alemtuzumab Treatment for Multiple Sclerosis: A Systematic Review and Meta-analysis

Immune thrombocytopenia is a significant adverse reaction secondary to multiple sclerosis. To evaluate the risk of secondary Immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab, we conducted a meta-analysis with subgroup and sensitivity analyses to assess the impact of relevant variables, such as region and study type. A total of 15 studies were included, encompassing 1,729 multiple sclerosis patients.This study found that there was a certain incidence of Immune thrombocytopenia in multiple sclerosis patients after treatment with alemtuzumab, and alemtuzumab may have some interference with platelet levels.Before initiating alemtuzumab, clinical physicians should perform a comprehensive assessment of the patient's benefit-to-risk ratio.